advocacy

BioAlberta works with policymakers at all levels for a coordinated approach to setting public policy initiatives and ensuring the life sciences industry’s critical issues are well represented.

Through our Advocacy and Policy Committee, BioAlberta focuses on legislative and regulatory policy at the provincial level.

However, we also work with partner life science organizations across the country to support federal regulatory issues. Our Advocacy and Policy Committee is divided into subcommittees to answer the unique needs of each of the life science sectors.

Priority activities include:

  • Coverage of critical legislation and regulatory policy
  • Educating public officials about biotechnology
  • Encouraging greater support for life sciences entrepreneurship
  • Simplifying the regulatory environment, among other issues

PMPRB

The Patented Medicine Prices Review Board (PMPRB) protects and informs Canadians by ensuring that the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends.

Leaving the Lab: Tracking the Decline in AMR R&D Professionals

The AMR Industry Alliance conducted a review of publicly available data on the state of AMR research and development talent. 

February 07, 2024

BioAlberta's Position Paper on Bioenergy Development in Alberta

BioAlberta is pleased to provide this position paper in response to the Government of Alberta’s Emissions
Reduction and Energy Development Plan1 and initiatives in support of advancing bioenergy development in the
province.

August 23, 2023

Investor Tools to Grow Alberta's Plant Protein Sector

This paper is continuation of our work for the plant-based ingredients that we started in 2019 with the assistance of Alberta Innovates that resulted in publishing the industry strategy and preliminary action plan titled Plant-Based Ingredients: Charting a Bold Path Forward. 

August 18, 2023

The Patented Medicine Prices Review Board has lost its way (again)

This commentary by W. Neil Palmer argues that the PMPRB has demonstrated little to no interest in patient health or health outcomes. It is time that changed.

November 1, 2022

Leaving the Lab: Tracking the Decline in AMR R&D Professionals

The AMR Industry Alliance conducted a review of publicly available data on the state of AMR research and development talent. 

August 23, 2023

BioAlberta's Position Paper on Bioenergy Development in Alberta

BioAlberta is pleased to provide this position paper in response to the Government of Alberta’s Emissions
Reduction and Energy Development Plan1 and initiatives in support of advancing bioenergy development in the
province.

August 23, 2023

Investor Tools to Grow Alberta's Plant Protein Sector

This paper is continuation of our work for the plant-based ingredients that we started in 2019 with the assistance of Alberta Innovates that resulted in publishing the industry strategy and preliminary action plan titled Plant-Based Ingredients: Charting a Bold Path Forward. 

August 18, 2023

The Patented Medicine Prices Review Board has lost its way (again)

This commentary by W. Neil Palmer argues that the PMPRB has demonstrated little to no interest in patient health or health outcomes. It is time that changed.

November 1, 2022